American Journal of Obstetrics and Gynecology
ResearchObstetricsAn automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia
Section snippets
Study population
Singleton pregnancies were enrolled at 5 participating European medical centers. An identical study protocol and data collection form was used at each center. The local ethics committees and institutional review boards approved the procedure, and all subjects gave their written, informed consent before participation. Background data on the patients were provided by the study centers in form of a completed case report form. A total of 351 individuals were enrolled in the study: 280 singleton
Demographic and clinical characteristics of the population
For the reference range study arm a total of 280 patients were included. For the case-control study arm 71 women with clinical PE and 268 women with uneventful pregnancies were included. No significant differences in age, gestational age at enrollment, or ethnical origin were observed. Women with PE had a higher systolic and diastolic blood pressure, had a lower mean birthweight of the neonate, and were less likely to smoke than normotensive women. The results are listed in Table 1.
Reference range for sFlt-1, PIGF, and sFlt-1/PIGF ratio in normal pregnancies using the Elecsys assay system
To assess
Comment
We report a new automated method for the measurement of sFlt-1 and PIGF using a commercially available immunoassay platform. A reference range for the determination of these analytes, as well as the sFlt-1/PIGF ratio as a function of gestational age, is reported. Moreover, we provide evidence that the serum concentrations of these analytes and the sFlt-1/PIGF ratio are significantly different in women with PE than in healthy pregnant women. The automated tests will allow a fast and
References (42)
- et al.
Pre-eclampsia
Lancet
(2005) - et al.
Prediction of adverse outcomes by common definitions of hypertension in pregnancy
Obstet Gynecol
(2001) - et al.
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies
Am J Obstet Gynecol
(2005) - et al.
Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia
Am J Obstet Gynecol
(2001) - et al.
Preeclampsia is associated with reduced serum levels of placenta growth factor
Am J Obstet Gynecol
(1998) - et al.
Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies
Am J Obstet Gynecol
(2003) - et al.
Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia
Am J Obstet Gynecol
(2005) - et al.
Placenta growth factor is not an early marker for the development of severe preeclampsia
Am J Obstet Gynecol
(2001) - et al.
Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia
Am J Obstet Gynecol
(2000) - et al.
Plasma placenta growth factor levels in midtrimester pregnancies
Obstet Gynecol
(2001)
Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia
Am J Obstet Gynecol
Mechanisms of disease: pre-eclampsia
Nat Clin Pract Nephrol
Summary of the NHLBI working group on research on hypertension during pregnancy
Hypertens Pregnancy
ACOG practice bulletin no. 33Diagnosis and management of preeclampsia and eclampsia, January 2002
Obstet Gynecol
Diagnosis and management of atypical preeclampsia-eclampsia
Am J Obstet Gynecol
ACOG committee opinion: antenatal corticosteroid therapy for fetal maturation
Int J Gynaecol Obstet
Changes in circulating level of IGF-I and IGF-binding protein-1 from the first to second trimester as predictors of preeclampsia
Eur J Endocrinol
Angiogenic factors for the prediction of preeclampsia in high-risk women
Am J Obstet Gynecol
Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor
J Clin Endocrinol Metab
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
J Clin Invest
Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia; young investigator award
Am J Obstet Gynecol
Cited by (0)
This study was sponsored by Roche, Penzberg, Germany.
Cite this article as: Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1-11.